



10574922 GAL: 1633

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid control number.

# Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: August 5, 2009

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/574,922
Filing Date	10/12/2004
First Named Inventor	Ralph Patrick BRAUN
Art Unit	1633
Examiner Name	Janice Li Qian
Attorney Docket Number	092633-0104

Sheet 1 of 2

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A1	WO 02/24232 A2	03/28/2002	Board of Regents, The Univ. of Texas System		
	A2	WO 02/11748 A1	02/14/2002	Sloan-Kettering Inst. For Cancer Research		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A3	Katsumi et al., Humoral and Cellular Immunity to an Encoded Protein Induced by Direct DNA Injection," <i>Human Gene Therapy</i> , Vol. 5, pp. 1335-1339 (1994).	
	A4	Abe et al., "Induction of Humoral and Cellular Anti-Idiotypic Immunity by Intradermal Injection of Naked DNA Encoding a Human Variable Region Gene Sequence of an Immunoglobulin Heavy Chain in a B Cell Malignancy," <i>Gene Therapy</i> , Vol. 3, pp. 988-993 (1996).	
	A5	[ABSTRACT ONLY] Inoue Tomoyuki et al., "Effect of Herpes Simplex Virus-1 gD or gD-IL-2 DNA Vaccine on Herpetic Keratitis," <i>US National Library of Medicine (NLM)</i> , Vol. 21, No. 7, pp. S79-S85 (2002).	
	A6	[ABSTRACT ONLY] Song Jianming et al., "pcDNA1 Genetic Immunization can Induce Specific Cell-Mediated Immune Responses in C57BL/6 Mice," <i>Biosciences Information Serv.</i> , Vol. 115, No. 11, pp. 1697-1700 (2002).	
	A7	[ABSTRACT ONLY] Ye Kai et al., "Immune Characteristics of Plasmid DNA Containing Plasmodium Falciparum Pf70 Gene Fragment," <i>Biosciences Information Service</i> , Vol. 23, No. 5, pp. 359-363 (2003).	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or other suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WASH\_5712578.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.L./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/574,922
		Filing Date	10/12/2004
		First Named Inventor	Ralph Patrick BRAUN
		Art Unit	1633
		Examiner Name	Janice Li Qian
Date Submitted: <u>August 5, 2009</u>		Attorney Docket Number	092633-0104
(use as many sheets as necessary)			
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>9</sup>
	A8	Hanke et al., "Lack of Toxicity and Persistence in the Mouse Associated with Administration of Candidate DNA-and Modified Vaccinia Virus Ankara (MVA)-based HIV Vaccines for Kenya," <i>Vaccine</i> 21, pp. 108-114 (2002).	
	A9	[ABSTRACT ONLY] Yang Huilan et al., "Construction and Expression of Herpes Simplex Virus Glycoprotein Polynucleotide Vaccine," <i>Biosciences Information Serv.</i> , Vol. 34, No. 1, pp. 53-54 (2001).	
	A10	[ABSTRACT ONLY] CUI, F.D. et al., "Intravascular Naked DNA Protective Humoral and Cellular Immunity Against Herpes Simplex Virus Type 1 Infection in Mice," <i>Biosciences Information Serv.</i> , Vol. 10, No. 25, pp. 2059-2066 (2003).	
	A11	Supplementary European Search Report for related European Patent Application No. 04 79 4672 dated November 27, 2008, 8 pgs.	

Examiner Signature	/Qian Janice Li/ (09/28/2009)	Date Considered
--------------------	-------------------------------	-----------------

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or other suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.